Ann: Syd Capital Markets Briefing Presentation, page-57

Perhaps I got a little excited on the close Friday. I was pretty confident of hitting the $16 range this week. No buyback notices lately so it's intriguing what the strategy is there? While I don't think the adolescent delay is overly critical, it's disappointing nonetheless- earliest approval date given was Jan 2023 I think, so 18 months later it's pretty hard to swallow for some and fair reason for holders to capitulate. Don't mind heading for the luxury market for the OTC lines but they do need to get more on board as the social media does seem a bit tardy in terms of followers ATM. As long as they keep ticking the boxes I'll be satisfied for now.